Why PROCEPT BioRobotics (PRCT) Is Up 8.3% After Raising 2025 Revenue Guidance

• Earlier this month, PROCEPT BioRobotics Corporation reported its second-quarter and first-half 2025 earnings, highlighting sales growth to US$79.18 million for the quarter and a narrowing net loss of US$19.58 million compared to the previous year.
• The company also raised its full-year 2025 revenue guidance to approximately US$325.5 million, reflecting confidence in sustained sales momentum and operational improvements.
• We'll now consider how this raised full-year revenue guidance could influence the investment narrative for PROCEPT BioRobotics going forward.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

PROCEPT BioRobotics Investment Narrative Recap

For shareholders in PROCEPT BioRobotics, belief rests on the potential for Aquablation therapy and the HYDROS platform to become a standard in urological care, supporting long-term growth through hospital adoption and expanded clinical indications. The company’s raised full-year revenue guidance to US$325.5 million signals continued sales momentum, though it does not meaningfully reduce the key short-term risk: ongoing operating losses and the challenge of reaching profitability as costs remain significant relative to revenue growth.

Among recent news, the successful completion of procedures in the WATER IV PCa Trial stands out, as positive clinical milestones are crucial for expanding Aquablation’s use cases and driving broader hospital adoption, an essential catalyst as PROCEPT seeks higher procedural volumes and improved margins.

However, while strong revenue trends offer optimism, investors should be aware that, unlike sales growth, the risk of persistent operating losses...

Read the full narrative on PROCEPT BioRobotics (it's free!)

PROCEPT BioRobotics' outlook anticipates $563.8 million in revenue and $70.0 million in earnings by 2028. This implies a 27.0% annual revenue growth rate and a $154.1 million increase in earnings from the current level of -$84.1 million.

Uncover how PROCEPT BioRobotics' forecasts yield a $66.22 fair value, a 59% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have valued PROCEPT BioRobotics between US$27.49 and US$66.22 across 3 estimates, reflecting wide differences in expectations. Even with strong sales forecasts, the ongoing unprofitability highlighted in recent results is a key consideration for those weighing the company’s future performance.

Explore 3 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth as much as 59% more than the current price!

Build Your Own PROCEPT BioRobotics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Find companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com